Skip to main content
Nicotine & Tobacco Research logoLink to Nicotine & Tobacco Research
. 2022 Jul 8;25(3):571–579. doi: 10.1093/ntr/ntac167

RETRACTED: Changes in Tobacco Dependence and Association With Onset and Progression of Use by Product Type From Wave 1 to Wave 3 of the Population Assessment of Tobacco and Health (PATH) Study

David R Strong 1,2,, John P Pierce 3, Martha White 4,5, Matthew D Stone 6, David B Abrams 7, Allison M Glasser 8, Olivia A Wackowski 9, K Michael Cummings 10, Andrew Hyland 11, Kristie Taylor 12, Kathryn C Edwards 13, Marushka L Silveira 14,15, Heather L Kimmel 16, Elizabeth Y Lambert 17, Wilson M Compton 18, Lynn C Hull 19, Raymond Niaura 20
PMCID: PMC10215975  PMID: 35801819

Abstract

Introduction

This study examined trajectories of tobacco dependence (TD) in relation to changes in tobacco product use and explored the effects of product-specific adding, switching, or discontinued use on dependence over time.

Aims and Methods

Data were analyzed from the first three waves of the Population Assessment of Tobacco and Health (PATH) Study, a nationally representative, longitudinal study of adults and youth in the United States. Data included 9556 Wave 1 (2013/2014) adult current established tobacco users who completed all three interviews and had established use at ≥2 assessments. Groups included cigarettes-only users, e-cigarettes-only users, cigars-only users, hookah-only users, any smokeless-only users, cigarette + e-cigarette dual users, and multiple product users. A validated 16-item scale assessed TD across product users.

Results

Wave 1 e-cigarette-only users’ who maintained exclusive e-cigarette use increased levels of TD through Wave 3 as did those who added or switched to another product. Wave 1 multiple product users’ TD decreased across waves. TD for all other Wave 1 user groups remained about the same. For Wave 1 cigarette-only smokers, switching to another product or moving to a pattern of no established use was associated with lower levels of TD than smokers whose use stayed the same. Movement to no established use of any tobacco product was consistently associated with lower TD for all other product users.

Conclusions

Except for Wave 1 e-cigarette-only users, TD among US tobacco product users was stable over time, with daily users less likely to vary from baseline.

Implications

The level of TD among most US tobacco users was stable over the first three waves of the PATH Study and trends in levels of TD were predominantly unrelated to changes in patterns of continued product use. Stable levels of TD suggest a population at persistent risk of health impacts from tobacco. Wave 1 e-cigarette users, including those maintaining exclusive e-cigarette use, experienced increasing levels of TD over time, perhaps because of increases in quantity or frequency of their e-cigarette product use or increasing efficiency of nicotine delivery over time.


This is a retraction to:

David R. Strong, PhD, John P. Pierce, PhD, Martha White, MS, Matthew D. Stone, PhD, David B. Abrams, PhD, Allison M. Glasser, MPH, Olivia A. Wackowski, PhD, MPH, K. Michael Cummings, PhD, Andrew Hyland, PhD, Kristie Taylor, PhD, Kathryn C. Edwards, PhD, Marushka L. Silveira, BDS, MPH, PhD, Heather L. Kimmel, PhD, Elizabeth Y. Lambert, MSc, Wilson M. Compton, MD, MPE, Lynn C. Hull, PhD, Raymond Niaura, PhD, Changes in Tobacco Dependence and Association With Onset and Progression of Use by Product Type From Wave 1 to Wave 3 of the Population Assessment of Tobacco and Health (PATH) Study, Nicotine & Tobacco Research, 2022, ntac167, https://doi.org/10.1093/ntr/ntac167

Following article publication, the authors became aware of an error in how the tobacco dependence data for some e-cigarette users was used in the analysis of this article. The authors immediately alerted the journal editor to this unintentional error, which they have determined materially impacts the conclusions and implications of the article. The authors are, therefore, retracting this article.

Contributor Information

David R Strong, Cancer Prevention and Control Program, Moores Cancer Center University of California, San Diego, CA, USA; Herbert Wertheim School of Public Health, University of California, San Diego, CA, USA.

John P Pierce, Herbert Wertheim School of Public Health, University of California, San Diego, CA, USA.

Martha White, Cancer Prevention and Control Program, Moores Cancer Center University of California, San Diego, CA, USA; Herbert Wertheim School of Public Health, University of California, San Diego, CA, USA.

Matthew D Stone, Herbert Wertheim School of Public Health, University of California, San Diego, CA, USA.

David B Abrams, School of Global Public Health, New York University, New York, NY, USA.

Allison M Glasser, School of Global Public Health, New York University, New York, NY, USA.

Olivia A Wackowski, Center for Tobacco Studies, Rutgers School of Public Health, New Brunswick, NJ, USA.

K Michael Cummings, Medical University of South Carolina, Charleston, SC, USA.

Andrew Hyland, Roswell Park Cancer Institute, Buffalo, NY, USA.

Kristie Taylor, Westat, Rockville, MD, USA.

Kathryn C Edwards, Westat, Rockville, MD, USA.

Marushka L Silveira, National Institute on Drug Abuse (NIDA/NIH), Bethesda, MD, USA; Kelly Government Solutions, Rockville, MD, USA.

Heather L Kimmel, National Institute on Drug Abuse (NIDA/NIH), Bethesda, MD, USA.

Elizabeth Y Lambert, National Institute on Drug Abuse (NIDA/NIH), Bethesda, MD, USA.

Wilson M Compton, National Institute on Drug Abuse (NIDA/NIH), Bethesda, MD, USA.

Lynn C Hull, Center for Tobacco Products, FDA, Silver Spring, MD, USA.

Raymond Niaura, School of Global Public Health, New York University, New York, NY, USA.


Articles from Nicotine & Tobacco Research are provided here courtesy of Oxford University Press

RESOURCES